

PRODUCT INFORMATION




AMG 337

Item No. 21333

CAS Registry No.: 1173699-31-4
Formal Name: 6-[(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one

MF: C₂₃H₂₂FN₇O₃
FW: 463.5
Purity: ≥98%
UV/Vis.: λ_{max}: 209, 249, 285, 344 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AMG 337 is supplied as a crystalline solid. A stock solution may be made by dissolving the AMG 337 in the solvent of choice, which should be purged with an inert gas. AMG 337 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of AMG 337 in ethanol is approximately 10 mg/ml and approximately 30 mg/ml in DMSO and DMF.

AMG 337 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AMG 337 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. AMG 337 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

AMG 337 is an orally active and selective inhibitor of c-Met kinase activity (IC₅₀ = 1 nM) and adaptor protein Gab-1 phosphorylation, which subsequently blocks downstream PI3K and MAPK pathways.¹ It has been shown to inhibit hepatocyte growth factor-mediated c-Met phosphorylation in PC3 cells (IC₅₀ = 5 nM) and to block tumor growth in a c-Met-dependent xenograft model in mice (ED₅₀ = 0.3 mg/kg).¹ AMG 337 has been used to inhibit cell proliferation in various c-Met-dependent tumor models.^{2,3}

References

1. Boezio, A.A., Copeland, K.W., Rex, K., *et al.* Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a potent and selective inhibitor of MET with high unbound target coverage and robust *in vivo* antitumor activity. *J. Med. Chem.* **59**(6), 2328-2342 (2016).
2. Hughes, P.E., Rex, K., Caenepeel, S., *et al.* *In vitro* and *in vivo* activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models. *Mol. Cancer Ther.* **15**(7), 1568-1579 (2016).
3. Caenepeel, S., Cooke, K., Wadsworth, S., *et al.* MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. *Oncotarget* (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM